• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2022.17043

Influence of chronic administration of antiparkinson drugs on levels of serum autoantibodies to dopamine and NMDA receptors

[Experimental medicine]
Mariya Baturina; Eduard Beyer; Sergey Alexandrovich Zhurbin; Maria Anatolievna Dergunova; Vladimir Baturin; Ekaterina Vladimirovna Grudina;

In experiments on 108 rats, changes in the level of serum autoantibodies to NMDA receptors (subunits NR1, NR2A, NR2B) and dopamine receptors of the first and second types (DR1 and DR2) were studied during chronic intraperitoneal administration of antipsychotics, antiparkinsonian drugs and their combination. The highest values of autoantibodies to NR1 and NR2A subunits were revealed when bromocriptine was used and to NR2B – when amantadine was administered. Chronic administration of haloperidol at a dose of 0.5 mg/kg increased serum levels of autoantibodies to NMDA receptors, especially in the NR2A subunit. At a dose of 0.1 mg/kg, haloperidol increased the content of autoantibodies to DR1 dopamine receptors. The use of an antipsychotic in combination with antiparkinsonian drugs led to an even more significant increase in the levels of autoantibodies to NR1, NR2A, DR1 and DR2, especially with the combined administration of bromocriptine and haloperidol. At the same time, haloperidol prevented the increase in autoantibodies to NR2B caused by antiparkinsonian drugs. The isolated use of haloperidol or bromocriptine, as well as their joint administration, increased the level of autoantibodies to the S100B protein in the blood serum, and amantadine eliminated this increase in autoantibodies. An increase in the concentration of autoantibodies to the S100B protein correlated with a high content of autoantibodies to NR1 and NR2A, as well as low content of NR2B.

Download

References:
1. Mayorova M. A., Butoma B. G., Churilov L. P., Gilburd B., Petrova N. N. [et al.] Autoimmune Concept of Schizophrenia: Historical Roots and Current Facets. Psychiatr. Danub. 2021;33(1):3-17. https://doi.org/10.24869/psyd.2021.3
2. Severance E. G., Yolken R. H. Role of Immune and Autoimmune Dysfunction in Schizophrenia. Handb. Behav. Neurosci. 2016;23:501-516. https://doi.org/10.1016/B978-0-12-800981-9.00029-8
3. Baturin V., Baturina M., Mamtseva G. I., Boev O., Yarovitsky V. [et al.] Levels of neurotropic autoantibodies in patients with schizophrenia. Medical News of North Caucasus. 2016;11(2):176-178. https://doi.org/10.14300/mnnc.2016.11030
4. Sinmaz N., Amatoury M., Merheb V., Ramanathan S., Dale R. C. [et al.] Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry. Ann. N. Y. Acad. Sci. 2015;1351:22-38. https://doi.org/10.1111/nyas.12764
5. Al-Diwani A., Pollak T. A., Langford A. E., Lennox B. R. Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses. Front. Psychiatry. 2017;8:13. https://doi.org/10.3389/fpsyt.2017.00013
6. Rosenthal-Simons A., Durrant A. R., Heresco-Levy U. Autoimmune-induced glutamatergic receptor dysfunctions: conceptual and psychiatric practice implications. Eur. Neuropsychopharmacol. 2013;23(12):1659-71. https://doi.org/10.1016/j.euroneuro.2013.05.008
7. Cox E. R., Marwick K. F. M., Hunter R. W., Priller J., Lawrie S. M. Dialysis and plasmapheresis for schizophrenia: a systematic review. Psychol. Med. 2020;50(8):1233-1240. https://doi.org/10.1017/S0033291720001324
8. Baturina M. V., Beyer E. V., Baturin V. A., Popov A. V. Dependence of the severity of haloperidol catalepsy on the activity of dopaminergic and glutamatergic systems of the brain of rats with prolonged use of antipsychotics. Medical News of North Caucasus. 2020;15(3):307-310. https://doi.org/10.14300/mnnc.2020.15073
9. Baturina M. V., Beyer E. V, Popov A. V., Baturin V. A., Boev O. I. Effect of chronic administration of haloperidol and risperidone on the number of dopamine receptors in rat brain tissue. Medical News of North Caucasus. 2019;14(4):697-698. https://doi.org/10.14300/mnnc.2019.14173
10. Hunter D., Jamet Z., Groc L. Autoimmunity and NMDA receptor in brain disorders: Where do we stand? Neurobiol. Dis. 2021;147:105161. https://doi.org/10.1016/j.nbd.2020.105161
11. Goodall E. F., Wang C., Simpson J. E., Baker D. J., Drew D. R. [et al.] Age-associated changes in the bloodbrain barrier: comparative studies in human and mouse. Neuropathol. Appl. Neurobiol. 2018;44(3):328-340. https://doi.org/10.1111/nan.12408
12. Glass L., Sinclair D., Boerrigter D., Naude K., Fung S. J. [et al.] Brain antibodies in the cortex and blood of people with schizophrenia and controls. Transl. Psychiatry. 2017;7(8):e1192. https://doi.org/10.1038/tp.2017.134
13. Matt S. M., Gaskill P. J. Where Is Dopamine and how do Immune Cells See it? Dopamine-Mediated Immune Cell Function in Health and Disease. J. Neuroimmune Pharmacol. 2020;15(1):114-164. https://doi.org/10.1007/s11481-019-09851-4
14. Liu Z., Zhai X. R., Du Z. S., Xu F. F., Huang Y. [et al.] Dopamine receptor D2 on CD4(+) T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease. Brain Behav. Immun. 2021;98:110-121. https://doi.org/10.1016/j.bbi.2021.08.220

Keywords: autoantibodies, dopamine receptors, NMDA receptors, S100B protein, haloperidol, bromocriptine, amantadine, L-DOPA